![Daniel R. Vlock](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel R. Vlock
Algemeen Directeur bij
ALOPEXX, INC.
Profiel
Daniel R.
Vlock is the founder of Alopexx Pharmaceuticals LLC, founded in 2006, serving as Chief Executive Officer; Alopexx Enterprises LLC, founded in 2006, serving as Chairman & Chief Executive Officer; and Alopexx, Inc., founded in 2006, serving as Chairman, President & Chief Executive Officer.
Current jobs include President & Chief Executive Officer at Alopexx Vaccines LLC, Chairman at Valerion Therapeutics LLC, and Chief Medical Officer at TransCode Therapeutics, Inc. since 2024.
Former jobs include Director at Kolltan Pharmaceuticals, Inc., Vice President-Clinical Research at ARIAD Pharmaceuticals, Inc., Principal at GPC Biotech, Inc., Pharmacia Corp., Ethicon Endo-Surgery, Inc., and Boehringer Ingelheim Corp., and Faculty Member at Yale University, Harvard Medical School, and the University of Pittsburgh School of Medicine.
Education includes undergraduate studies at Cornell University and a doctorate from Baylor College of Medicine.
Actieve functies van Daniel R. Vlock
| Bedrijven | Functie | Begin |
|---|---|---|
| ALOPEXX, INC. | Algemeen Directeur | 01-01-2021 |
| TRANSCODE THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 28-03-2024 |
Valerion Therapeutics LLC
 Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Develops targeted therapies for orphan genetic diseases | Voorzitter | - |
Alopexx Vaccines LLC | Algemeen Directeur | - |
Alopexx Enterprises LLC
 Alopexx Enterprises LLC BiotechnologyHealth Technology Engages in investing and managing health care companies | Algemeen Directeur | 01-01-2006 |
Alopexx Pharmaceuticals LLC
 Alopexx Pharmaceuticals LLC Aerospace & DefenseElectronic Technology Part of Alopexx Enterprises LLC, Alopexx Pharmaceuticals LLC is a biotechnology company based in MA. Alopexx Pharmaceuticals LLC specializes in the development of immune therapeutics for microbial diseases. Founded in 2011 by Daniel R. Vlock, Alopexx focuses on creating broad-spectrum immune approaches to prevent and treat bacterial, fungal, and parasitic infections. The company's technology targets the surface polysaccharide, poly N-acetyl glucosamine (Pnag), which is present on over 75 distinct pathogens. Alopexx's product pipeline includes a fully human monoclonal antibody, F598, and a vaccine candidate, Av0328, both of which have shown promising results in clinical trials. The company aims to reduce the reliance on antibiotics by developing therapies that utilize the host's immune system, thereby preventing the development of antibiotic resistance. Daniel R. Vlock has been the CEO since incorporation. | Algemeen Directeur | 01-10-2011 |
Eerdere bekende functies van Daniel R. Vlock
| Bedrijven | Functie | Einde |
|---|---|---|
GPC Biotech, Inc.
 GPC Biotech, Inc. Drugstore ChainsRetail Trade Develops anticancer drugs | Corporate Officer/Principal | - |
| ARIAD PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Directeur/Bestuurslid | - |
| ░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van Daniel R. Vlock
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
7
Eerstegraads connecties
17
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 17 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Health Technology |
GPC Biotech, Inc.
GPC Biotech, Inc. Drugstore ChainsRetail Trade Develops anticancer drugs | Retail Trade |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Researches, manufactures and sells pharmaceuticals | Health Technology |
Ethicon Endo-Surgery, Inc.
 Ethicon Endo-Surgery, Inc. Medical SpecialtiesHealth Technology Manufactures surgical devices and equipments | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baylor College of Medicine
 Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products | Health Technology |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Valerion Therapeutics LLC
Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Develops targeted therapies for orphan genetic diseases | Health Technology |
Alopexx Pharmaceuticals LLC
Alopexx Pharmaceuticals LLC Aerospace & DefenseElectronic Technology Part of Alopexx Enterprises LLC, Alopexx Pharmaceuticals LLC is a biotechnology company based in MA. Alopexx Pharmaceuticals LLC specializes in the development of immune therapeutics for microbial diseases. Founded in 2011 by Daniel R. Vlock, Alopexx focuses on creating broad-spectrum immune approaches to prevent and treat bacterial, fungal, and parasitic infections. The company's technology targets the surface polysaccharide, poly N-acetyl glucosamine (Pnag), which is present on over 75 distinct pathogens. Alopexx's product pipeline includes a fully human monoclonal antibody, F598, and a vaccine candidate, Av0328, both of which have shown promising results in clinical trials. The company aims to reduce the reliance on antibiotics by developing therapies that utilize the host's immune system, thereby preventing the development of antibiotic resistance. Daniel R. Vlock has been the CEO since incorporation. | Electronic Technology |
University of Pittsburgh School of Medicine
 University of Pittsburgh School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alopexx Enterprises LLC
Alopexx Enterprises LLC BiotechnologyHealth Technology Engages in investing and managing health care companies | Health Technology |
TransCode Therapeutics, Inc.
 TransCode Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes diagnostics and therapeutics for the detection and treatment of cancer | Health Technology |
Alopexx Vaccines LLC | |
Alopexx, Inc.
 Alopexx, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company which develops novel and broad-spectrum immune-mediated therapeutics | Health Technology |
Kies MarketScreener 
